Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Drug Profile

Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Alternative Names: CRISPR/Cas9-based CAR-T cell therapies - Intellia Therapeutics/Novartis; CRISPR/Cas9-based haematopoietic stem cell therapies - Intellia Therapeutics/Novartis

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellia Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Stem cell therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 25 Jun 2017 University of California, University of Vienna and Charpentier submit appellate brief seeking reversal of decision by PTAB, which dismissed interference proceedings against Broad Institute, MIT and Harvard University for a patent related to CRISPR-Cas9 genome editing technology, in USA
  • 19 Jun 2017 China’s State Intellectual Property Office ("SIPO") announced its intention to grant a patent for CRISPR/Cas9 genome editing technology
  • 02 May 2017 Vilnius University has patent protection for CRISPR-Cas9 genome editing in USa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top